vs
Masco（MAS）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
Masco的季度营收约是百利高的1.7倍（$1.9B vs $1.1B），Masco净利率更高（11.9% vs -127.8%，领先139.7%），Masco同比增速更快（6.5% vs -2.5%），过去两年百利高的营收复合增速更高（1.3% vs -4.2%）
美国家居建材企业Masco主营家装及新建住宅市场相关产品，旗下拥有20余家子公司，在全球运营近80座生产工厂，其中美国本土近60座，海外地区超20座。公司1969年于纽交所挂牌上市，后实现快速增长，成功跻身美国财富500强榜单。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
MAS vs PRGO — 直观对比
营收规模更大
MAS
是对方的1.7倍
$1.1B
营收增速更快
MAS
高出9.0%
-2.5%
净利率更高
MAS
高出139.7%
-127.8%
两年增速更快
PRGO
近两年复合增速
-4.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $1.1B |
| 净利润 | $228.0M | $-1.4B |
| 毛利率 | 35.8% | 32.6% |
| 营业利润率 | 16.5% | -116.0% |
| 净利率 | 11.9% | -127.8% |
| 营收同比 | 6.5% | -2.5% |
| 净利润同比 | 14.5% | -3093.9% |
| 每股收益（稀释后） | — | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MASPRGO
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.8B | $1.1B | ||
| Q3 25 | $1.9B | $1.0B | ||
| Q2 25 | $2.1B | $1.1B | ||
| Q1 25 | $1.8B | $1.0B | ||
| Q4 24 | $1.8B | $1.1B | ||
| Q3 24 | $2.0B | $1.1B | ||
| Q2 24 | $2.1B | $1.1B |
净利润MASPRGO
| Q1 26 | $228.0M | — | ||
| Q4 25 | $165.0M | $-1.4B | ||
| Q3 25 | $189.0M | $7.5M | ||
| Q2 25 | $270.0M | $-8.4M | ||
| Q1 25 | $186.0M | $-6.4M | ||
| Q4 24 | $182.0M | $-44.4M | ||
| Q3 24 | $167.0M | $-21.0M | ||
| Q2 24 | $258.0M | $-108.4M |
毛利率MASPRGO
| Q1 26 | 35.8% | — | ||
| Q4 25 | 33.9% | 32.6% | ||
| Q3 25 | 34.2% | 36.1% | ||
| Q2 25 | 37.6% | 34.4% | ||
| Q1 25 | 35.8% | 37.6% | ||
| Q4 24 | 34.8% | 33.9% | ||
| Q3 24 | 36.6% | 37.2% | ||
| Q2 24 | 37.5% | 37.0% |
营业利润率MASPRGO
| Q1 26 | 16.5% | — | ||
| Q4 25 | 13.8% | -116.0% | ||
| Q3 25 | 15.8% | 7.0% | ||
| Q2 25 | 20.1% | 4.3% | ||
| Q1 25 | 15.9% | 4.5% | ||
| Q4 24 | 15.9% | 10.0% | ||
| Q3 24 | 18.0% | 7.4% | ||
| Q2 24 | 19.0% | -2.5% |
净利率MASPRGO
| Q1 26 | 11.9% | — | ||
| Q4 25 | 9.2% | -127.8% | ||
| Q3 25 | 9.9% | 0.7% | ||
| Q2 25 | 13.2% | -0.8% | ||
| Q1 25 | 10.3% | -0.6% | ||
| Q4 24 | 10.0% | -3.9% | ||
| Q3 24 | 8.4% | -1.9% | ||
| Q2 24 | 12.3% | -10.2% |
每股收益（稀释后）MASPRGO
| Q1 26 | — | — | ||
| Q4 25 | $0.81 | $-10.23 | ||
| Q3 25 | $0.90 | $0.05 | ||
| Q2 25 | $1.28 | $-0.06 | ||
| Q1 25 | $0.87 | $-0.05 | ||
| Q4 24 | $0.85 | $-0.32 | ||
| Q3 24 | $0.77 | $-0.15 | ||
| Q2 24 | $1.17 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | $2.9B | — |
| 股东权益账面价值 | $27.0M | $2.9B |
| 总资产 | $5.2B | $8.5B |
| 负债/权益比越低杠杆越低 | 109.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MASPRGO
| Q1 26 | — | — | ||
| Q4 25 | $647.0M | — | ||
| Q3 25 | $559.0M | $432.1M | ||
| Q2 25 | $390.0M | $454.2M | ||
| Q1 25 | $377.0M | $409.9M | ||
| Q4 24 | $634.0M | $558.8M | ||
| Q3 24 | $646.0M | $1.5B | ||
| Q2 24 | $398.0M | $542.8M |
总债务MASPRGO
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.9B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MASPRGO
| Q1 26 | $27.0M | — | ||
| Q4 25 | $-185.0M | $2.9B | ||
| Q3 25 | $-78.0M | $4.4B | ||
| Q2 25 | $-84.0M | $4.5B | ||
| Q1 25 | $-254.0M | $4.4B | ||
| Q4 24 | $-279.0M | $4.3B | ||
| Q3 24 | $-88.0M | $4.6B | ||
| Q2 24 | $-26.0M | $4.5B |
总资产MASPRGO
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.2B | $8.5B | ||
| Q3 25 | $5.3B | $10.1B | ||
| Q2 25 | $5.3B | $10.1B | ||
| Q1 25 | $5.1B | $9.8B | ||
| Q4 24 | $5.0B | $9.6B | ||
| Q3 24 | $5.3B | $11.2B | ||
| Q2 24 | $5.4B | $10.4B |
负债/权益比MASPRGO
| Q1 26 | 109.07× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $175.4M |
| 自由现金流经营现金流 - 资本支出 | — | $148.6M |
| 自由现金流率自由现金流/营收 | — | 13.4% |
| 资本支出强度资本支出/营收 | 1.8% | 2.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $145.1M |
8季度趋势，按日历期对齐
经营现金流MASPRGO
| Q1 26 | — | — | ||
| Q4 25 | $418.0M | $175.4M | ||
| Q3 25 | $456.0M | $51.7M | ||
| Q2 25 | $306.0M | $75.9M | ||
| Q1 25 | $-158.0M | $-64.5M | ||
| Q4 24 | $407.0M | $312.6M | ||
| Q3 24 | $416.0M | $42.2M | ||
| Q2 24 | $346.0M | $9.5M |
自由现金流MASPRGO
| Q1 26 | — | — | ||
| Q4 25 | $371.0M | $148.6M | ||
| Q3 25 | $415.0M | $29.8M | ||
| Q2 25 | $270.0M | $56.7M | ||
| Q1 25 | $-190.0M | $-90.0M | ||
| Q4 24 | $351.0M | $274.9M | ||
| Q3 24 | $378.0M | $15.1M | ||
| Q2 24 | $303.0M | $-18.9M |
自由现金流率MASPRGO
| Q1 26 | — | — | ||
| Q4 25 | 20.7% | 13.4% | ||
| Q3 25 | 21.6% | 2.9% | ||
| Q2 25 | 13.2% | 5.4% | ||
| Q1 25 | -10.5% | -8.6% | ||
| Q4 24 | 19.2% | 24.2% | ||
| Q3 24 | 19.1% | 1.4% | ||
| Q2 24 | 14.5% | -1.8% |
资本支出强度MASPRGO
| Q1 26 | 1.8% | — | ||
| Q4 25 | 2.6% | 2.4% | ||
| Q3 25 | 2.1% | 2.1% | ||
| Q2 25 | 1.8% | 1.8% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 3.1% | 3.3% | ||
| Q3 24 | 1.9% | 2.5% | ||
| Q2 24 | 2.1% | 2.7% |
现金转化率MASPRGO
| Q1 26 | — | — | ||
| Q4 25 | 2.53× | — | ||
| Q3 25 | 2.41× | 6.89× | ||
| Q2 25 | 1.13× | — | ||
| Q1 25 | -0.85× | — | ||
| Q4 24 | 2.24× | — | ||
| Q3 24 | 2.49× | — | ||
| Q2 24 | 1.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAS
暂无分部数据
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
